Records containing: Melanoma
This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.
Follow recorded terms in Drug Alerts for Android. Free includes unlimited local condition follows and an on-open recent-record watchlist. Plus adds no ads and personal organization tools.
All
FDA submission records
EMA medicine records
ClinicalTrials.gov record updates
ClinicalTrials.gov records with results posted
-
CLINICAL_TRIALS study record update · 2022-03-17Individual Patient Compassionate Use of GX-I7
-
CLINICAL_TRIALS study record update · 2022-03-16Integrated Basic Science Within the Instructional Design of Pattern Recognition Training in Visual Diagnostics: Effect on Learning Curve Steepness, Plateau and Retrieval
-
CLINICAL_TRIALS study record update · 2022-02-28Yervoy® Postmarketing Surveillance for Patients in Japan With Unresectable, Malignant Melanoma
-
CLINICAL_TRIALS study record update · 2022-02-24Phase I-II Study of the Combination Vemurafenib Plus Cobimetinib Plus PEG-interferon in Advanced Melanoma Patients Harboring the V600BRAF Mutation
-
CLINICAL_TRIALS study record update · 2022-02-11Personalized Immune Cell Therapy Targeting Neoantigen of Malignant Solid Tumors
- Organize your saved records without ads with Plus.
-
CLINICAL_TRIALS study record update · 2022-02-10Understanding the Treatment Patterns, Healthcare Resource Utilization, Costs of Care, and Clinical Outcomes Among Patients Treated for Advanced Melanoma
-
CLINICAL_TRIALS study record update · 2022-02-08A Phase 1, Open-Label, Dose Escalation Study of MGA271 in Combination With Ipilimumab in Patients With Melanoma, Non-Small Cell Lung Cancer, and Other Cancers
-
CLINICAL_TRIALS study record update · 2022-02-08Phase 1, First-in-Human, Open Label, Dose Escalation Study of MGD009, A Humanized B7-H3 x CD3 Dual-Affinity Re-Targeting (DART) Protein in Patients With Unresectable or Metastatic B7-H3-Expressing Neoplasms
-
CLINICAL_TRIALS study record update · 2022-02-08Phase II Study of Abraxane Plus Ipilimumab in Patients With Metastatic Melanoma
-
CLINICAL_TRIALS study record update · 2022-02-08A Phase 1 Dose Escalation Study of MGA271 in Refractory Cancer
-
CLINICAL_TRIALS study record update · 2022-02-08A Tissue Procurement and Examination Substudy of Study CP-MGA271-01 (NCT01391143)
-
CLINICAL_TRIALS study record update · 2022-02-04Phase I Study of Vaccine Enriched, Autologous, Activated T-Cells Redirected to the Tumor Marker GD2 in Patients With Relapsed/Refractory Melanoma
-
CLINICAL_TRIALS study record update · 2022-02-01Safety and Efficacy of Recombinant L-IFN Adenovirus Injection in Relapsed/Refractory Solid Tumors: a Single/Multicenter, Dose-increasing, Cohort Extension Clinical Study
-
CLINICAL_TRIALS study record update · 2022-01-26Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum
-
CLINICAL_TRIALS study record update · 2022-01-04SunSmart Intervention in Schools
-
CLINICAL_TRIALS study record update · 2022-01-03Dose-seeking Study of Pembrolizumab Plus Vemurafenib and Cobimetinib for Therapy of Advanced Melanoma
-
CLINICAL_TRIALS study record update · 2021-12-28Observational Study of Genetic Predictors of Efficiency and Safety of Immune Checkpoints Inhibitors in Patients With Different Malignancies (ICIPRESIST-0519)
-
CLINICAL_TRIALS study record update · 2021-12-09Induction of Antitumor Response in Melanoma Patients Using the Antimicrobial Peptide LL37
-
CLINICAL_TRIALS study record update · 2021-12-01A Randomized, Single-center, Open-label, Single Dose, Two-period, Crossover Study to Investigate the Relative Bioavailability of Binimetinib 3 x15 mg and 45 mg Tablets in Healthy Participants
-
CLINICAL_TRIALS study record update · 2021-11-23Targeted Melanoma Detection With Skin Self-examination: Leveraging the Mammogram Encounter
-
CLINICAL_TRIALS study record update · 2021-11-22FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors
-
CLINICAL_TRIALS study record update · 2021-11-16A Phase II, Open-Label, Multicenter, Randomized Study of CDX-1401, a Dendritic Cell Targeting NY-ESO-1 Vaccine, in Patients With Malignant Melanoma Pre-Treated With Recombinant CDX-301, a Recombinant Human Flt3 Ligand
-
CLINICAL_TRIALS study record update · 2021-11-15A Phase 1, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN02390 in Participants With Select Advanced Malignancies
-
CLINICAL_TRIALS study record update · 2021-11-11Safety and Efficacy of Chimeric Antigen Receptor T Lymphocytes for Patients With Intermediate and Advanced Tumors
-
CLINICAL_TRIALS study record update · 2021-11-10Generation of Cancer Antigen-Specific T-cells From Human Induced Pluripotent Stem Cells (iPSC) for Research and Potential Future Therapy